Stephen D'Amico - JoVE Visualize

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Biorxiv : the Preprint Server for Biology|March 10, 2025

STAT3 Sustains Tumorigenicity Following Mutant KRAS AblationStephen D'Amico, Varvara Kirillov, Jingxuan Liu, et al.

Nature Communications|March 6, 2021

KRAS drives immune evasion in a genetic model of pancreatic cancerIrene Ischenko, Stephen D'Amico, Manisha Rao, et al.

CNS Spectrums|October 17, 2015

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II resultsRachelle S Doody, Stephen D'Amico, Andrew J Cutler, et al.

BMC Neurology|June 10, 2016

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injuryFlora M Hammond, David N Alexander, Andrew J Cutler, et al.

Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Biorxiv : the Preprint Server for Biology|March 10, 2025

STAT3 Sustains Tumorigenicity Following Mutant KRAS AblationStephen D'Amico, Varvara Kirillov, Jingxuan Liu, et al.

Nature Communications|March 6, 2021

KRAS drives immune evasion in a genetic model of pancreatic cancerIrene Ischenko, Stephen D'Amico, Manisha Rao, et al.

CNS Spectrums|October 17, 2015

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II resultsRachelle S Doody, Stephen D'Amico, Andrew J Cutler, et al.

BMC Neurology|June 10, 2016

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injuryFlora M Hammond, David N Alexander, Andrew J Cutler, et al.

Pageof 2